Elon Musk has publicly responded to reports alleging his use of recreational drugs during his tenure within the U.S. government, specifically referencing substances such as ketamine, ecstasy, and psychedelic mushrooms.
According to reports, concerns were raised about Musk’s drug consumption considering his pivotal role in leading the so-called “Department of Government Efficiency.” His daily medication regimen, reportedly comprising approximately 20 pills including Adderall, further fueled speculation surrounding his substance use.
In an interview in early 2024, Musk admitted to using ketamine in small, controlled doses biweekly to manage workload demands, emphasizing that excessive intake hinders productivity. However, insiders suggest a higher frequency of use, potentially daily, which allegedly impacted his health.
Musk’s increased engagement in the administration coincided with growing unease over his conduct, including reports of disrespectful behavior towards cabinet members and controversial gestures at public events. Observers and former associates have expressed concerns about his judgment and moral compass during this period.
It is important to note that substances like ecstasy are classified as Schedule I controlled substances under federal law, strictly prohibiting their use by government employees. While Musk’s position as a special government employee may have exempted him from certain restrictions, recreational use of Schedule III substances like ketamine would typically contravene federal workplace policies.
Following his departure from governmental duties, questions have emerged about the implications of his drug use on his professional responsibilities and effectiveness. Reports mention that he was afforded advance notice of random drug testing, potentially compromising their integrity.
When confronted with the allegations during his farewell address, Musk dismissed the claims as false reporting tied to a publication he challenged for prior journalistic inaccuracies. The White House declined to comment directly on the matter, redirecting attention to broader policy issues.
This episode highlights ongoing discussions about the intersection of leadership accountability, substance use, and public trust within high-profile government roles.
